Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory Colorectal and Appendiceal Carcinomatosis: Secondary Analysis of the US PIPAC Collaborative Phase 1 Trial
Compared with ST, PIPAC was associated with higher number of good days, reduced hospitalization burden, and longer OS without a negative impact on HRQoL with repeated PIPACs. These findings are foundational for evaluation of PIPAC in a randomized clinical trial.
Authors
- Richard L. Whelan (ORCID: https://orcid.org/0000-0002-9707-4967)
- Yuman Fong (ORCID: https://orcid.org/0000-0002-8934-9959)
- Amit Merchea (ORCID: https://orcid.org/0000-0001-7880-7080)
- Muhammad Talha Waheed (ORCID: https://orcid.org/0000-0002-0679-4396)
- Robert S. Krouse (ORCID: https://orcid.org/0000-0002-7176-461X)
- Thanh H. Dellinger (ORCID: https://orcid.org/0000-0003-1855-1989)
- Marwan Fakih (ORCID: https://orcid.org/0000-0002-6554-5488)
- Nora Ruel (ORCID: https://orcid.org/0000-0002-4591-3618)
- Danielle K. DePeralta (ORCID: https://orcid.org/0000-0001-5990-0124)
- Mustafa Raoof (ORCID: https://orcid.org/0000-0003-4710-2226)
- Virginia Chih-Yi Sun (ORCID: https://orcid.org/0000-0003-3129-4235)
Institutions
- City Of Hope National Medical Center (US)
- Northwell Health (US)
- WinnMed (US)
- Mayo Clinic in Florida (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1245/s10434-024-15980-9
- Citations
- 8
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 4.58
Funders
- City of Hope